PDS Biotechnology Corporation — Form 8-K Summary
Reporting date: October 6, 2026. This current report concerns an announced investor and medical-community event, not a financial results filing.
Business context and event
PDS Biotechnology said it would host a virtual key opinion leader event featuring Jonathan M. Hernandez, M.D., an investigator in the Surgical Oncology Program at the National Cancer Institute’s Center for Cancer Research. Dr. Hernandez and company management are scheduled to discuss clinical outcomes from PDS0301 Phase 2 trials for advanced liver-associated cancers, with emphasis on the metastatic colorectal cancer (mCRC) cohort.
Financial performance and changes
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics. It reports no financial-period comparison or material financial changes.
Outlook, risks, and contingencies
No financial guidance, business outlook, risk update, or contingency is provided in the supplied filing text. The filing does not include the clinical outcome data or event logistics; it identifies the October 6 press release as Exhibit 99.1.
Investor facts to verify
- Review Exhibit 99.1 for the event date, time, access details, and any additional company statements.
- Consult the underlying clinical data for the PDS0301 Phase 2 trials, particularly the mCRC cohort, including endpoints, patient numbers, and safety results.
- Check subsequent filings and company disclosures for financial results or updates not covered by this 8-K.